Lamivudine
ART
Prism Health North TexasSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the ART cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tenofovir Alafenamide Prism Health North Texas | Phase 3 | B |
TENOFOVIR DISOPROXIL FUMARATE Prism Health North Texas | Phase 3 | B |
(±)-FTC Prism Health North Texas | Phase 3 | B |
Doravirine Prism Health North Texas | Phase 3 | B |
Bictegravir Prism Health North Texas | Phase 3 | B |
Sitagliptin Shahid Beheshti University of Medical Sciences | Phase 1/2 | CCC |
Letrozole Shahid Beheshti University of Medical Sciences | Phase 1/2 | CCC |
Metformin Shahid Beheshti University of Medical Sciences | Phase 1/2 | CCC |
Same molecule, other indications
Lamivudine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →